Compare BioNTech SE - ADR (BNTX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Sirius XM Holdings Inc — how do they compare? BioNTech SE - ADR trades at $93.17 (market cap $23.31B), while Sirius XM Holdings Inc trades at $28.34 (market cap $9.70B). The key difference: BioNTech SE - ADR is far larger — about 2.4× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SIRI | |
|---|---|---|
Market Cap | $23.31B | $9.70B |
Sector | Health | Media |
52-Week High | $119.34 | $32.59 |
52-Week Low | $83.89 | $19.92 |
Enterprise Value | $6.60B | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Sirius XM Holdings (SIRI) trades at $28.275, down 1.75% today, with a bearish technical signal and mixed earnings history including a Q2 2026 miss. The company maintains stable cash flow, with Q2 revenue up 1% year-over-year and raised 2026 guidance. Valuation appears attractive with a P/E of 11.56 and P/B below 1, while a $0.27 dividend provides income support.
Outlook: SIRI offers value with solid fundamentals and shareholder returns, but faces competitive pressures and subscriber volatility. Risks include high debt and market sentiment shifts. Analysts see 17% upside to the $33.17 consensus target, supporting a cautious buy view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
